Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of slow-growing lymphoma called MALT (mucosa-associated lymphoid tissue) extranodal marginal zone lymphoma, confirmed by a tissue biopsy.
• People who have either been newly diagnosed with advanced-stage MALT lymphoma (stage III or IV) or whose MALT lymphoma has come back after local treatment.
• People who have not previously received any systemic (whole-body) drug treatment for their lymphoma — though treatment to clear a stomach bacteria called H. pylori is allowed for those with stomach MALT lymphoma related to that infection.
• People whose lymphoma has not transformed into a more aggressive (high-grade) type.
• People who have at least one measurable area of lymphoma that can be tracked during the trial.
• People aged 18 or older, of any gender.
• People who are reasonably well and able to carry out daily activities, as measured by a standard medical scoring system called ECOG, with a score of 0, 1, or 2 (confirm with trial site).
• People whose doctors expect them to survive for more than 12 months.
• People whose bone marrow, heart, lungs, liver, and kidneys are functioning well enough to safely participate.
• People who are willing to take part, have been fully informed about the study, have signed a consent form, and are able to follow all study procedures.

Who may not be able to join:

• People who have had a stroke, bleeding in the brain, or who have taken the blood-thinning medication warfarin in the past 6 months.
• People whose lymphoma has spread to the brain or central nervous system.
• People who have previously had a stem cell transplant from a donor (allogeneic transplant).
• People who have previously been treated with a type of drug called a BTK inhibitor, or with a CD20 monoclonal antibody therapy (a specific type of immune-based cancer treatment).
• People who currently have an active infection, other than a fever that is related to the lymphoma itself.
• People who have or have had another cancer, unless it was cervical carcinoma in situ or basal cell skin cancer that has been fully cured.
• People who are currently taking certain strong medications that affect how the body breaks down drugs, known as potent cytochrome P450 inhibitors (confirm with trial site).
• People with serious heart conditions, such as uncontrolled or symptomatic irregular heartbeat, heart failure, or a heart attack within the past 12 months.
• People who, in the treating doctor's judgement, have significant organ problems, uncontrolled other health conditions that could pose a safety risk, or difficulties absorbing or processing the trial drug Zanubrutinib.
• Women who are pregnant or breastfeeding, or women who could become pregnant and are unwilling to use contraception during the trial.
• People who have received any anti-cancer treatment within the 4 weeks before enrolling in the trial.
• People with active chronic hepatitis B or active hepatitis C.
• People who have received steroid treatment or other immune-suppressing medications within the 14 days before starting the study treatment.

Important: Always verify eligibility with the trial site directly before applying.